EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Alaunos Therapeutics's enterprise value is $1.33 Mil.
Alaunos Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.01 Mil. Therefore, Alaunos Therapeutics's EV-to-Revenue for today is 133.20.
The historical rank and industry rank for Alaunos Therapeutics's EV-to-Revenue or its related term are showing as below:
TCRT'
s EV-to-Revenue Range Over the Past 10 Years
Min: 4.39 Med: 346.91 Max: 7226.47
Current: 133.2
During the past 13 years, the highest EV-to-Revenue of Alaunos Therapeutics was 7226.47. The lowest was 4.39. And the median was 346.91.
TCRT's EV-to-Revenue is ranked worse than 89.05% of 995
companies
in the Biotechnology industry
Industry Median: 7.63
vs TCRT: 133.20
Alaunos Therapeutics EV-to-Revenue Historical Data
The historical data trend for Alaunos Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alaunos Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Alaunos Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alaunos Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Alaunos Therapeutics's EV-to-Revenue falls into.
Alaunos Therapeutics's current Enterprise Value is $1.33 Mil.
Alaunos Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alaunos Therapeutics's share price for today is $5.02.
Alaunos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alaunos Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Alaunos Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TCRT has been successfully added to your 